Novo Nordisk Finance (Netherlands) B.V., founded in 1999 and based in Amsterdam, serves as the financing arm of Novo Nordisk A/S, a global leader in diabetes care and hormone replacement therapies. The company primarily focuses on providing financial support to its parent company's operations while managing a diverse portfolio of funding instruments.
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Historically, Novo Nordisk Finance has been a significant player in the bond market, issuing its first bonds in 2000. Notable issuances include a €1 billion 10-year bond in 2019, which was well-received and reflects competitive yields compared to industry standards. Most recently, the issuer has focused on sustainability-linked bonds, aligning with the parent company’s commitment to environmental responsibility. Current yields remain attractive for investors seeking stable returns in a low-interest-rate environment.